Review Of PT-141 Bremelanotide – Buy PT-141 10MG Peptide (USA Made)
29March 29, 2023
Research Overview Of PT-141 Bremelanotide – Laboratory-Grade PT-141 10MG Peptide (USA Manufactured)
PT-141, also known as bremelanotide, is a synthetic melanocortin receptor agonist developed for investigation into hypoactive sexual desire disorder and related functions in research models. Laboratory studies suggest PT-141 exhibits interesting properties when examined in various research contexts, including its potential applications in sexual dysfunction research.
At Loti Labs, we prioritize stocking high-quality research chemicals for scientific inquiry. Our PT-141 is available exclusively for research purposes and not intended for use outside controlled laboratory settings. This compound is supplied in lyophilized powder form and distributed in 10 mg vials for research applications only.
What is PT-141 (Bremelanotide) and Its Research Applications in Laboratory Studies for Female Sexual Dysfunction?
PT-141 is a synthetic seven amino acid peptide that has been investigated in laboratory settings as a possible substance for studying sexual function mechanisms in premenopausal animal models. Research suggests that PT-141 may influence sexual arousal pathways in these models under controlled laboratory conditions.
While conducting investigations on PT-141 in male rats and non-human primates, researchers observed notable physiological responses. The preliminary findings suggest that PT-141 represents a potential avenue for further investigation. Additionally, laboratory studies have shown promising results in male rat and non-human primate models.
Definition of PT-141 as a Melanocortin Receptor Agonist
Explanation of Its Role in Treating Hypoactive Sexual Desire Disorder and Erectile Dysfunction
Research suggests PT-141 may have applications in studying hypoactive sexual desire disorder (HSDD) mechanisms in laboratory models. HSDD is characterized by a persistent lack of sexual desire that causes significant distress. In research settings, PT-141 works by enhancing the activity of melanocortin receptors in the brain, which may help restore normal sexual desire function in experimental models. Beyond its application in HSDD research, PT-141 is also being investigated in laboratory settings for erectile dysfunction (ED) mechanisms. ED is defined by the inability to achieve or maintain an erection sufficient for satisfactory performance. Research suggests PT-141 may influence erectile function by affecting blood flow and enhancing natural responses to stimulation in research models, offering a novel approach to studying this condition.
STRUCTURE OF PT-141
Molecular Formula: C50H68N14O10
Molecular weight: 1025.2 g/mol
CAS number: 189691-06-3
IUPAC name: (3S,6S,9R,12S,15S,23S)-15-[[(2S)-2-acetamidohexanoyl]amino]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,17-hexaoxo-1,4,7,10,13,18-hexazacyclotricosane-23-carboxylic acid
In laboratory settings, PT-141 functions as an agonist of several melanocortin receptors, which in order of potency are MC1R, MC4R, MC3R, MC5R, and MC2R. The mechanisms underlying PT-141’s actions in laboratory models are still under investigation.
One theoretical pathway involves stimulation of dopamine in the medial preoptic area, which has been implicated in various behavioral responses observed in research organisms.
How PT-141 Functions in Research Models
PT-141, also known as bremelanotide, is a synthetic peptide that operates by activating melanocortin receptors in research models. These receptors play important roles in various physiological processes that scientists are actively studying. When PT-141 binds to these receptors in laboratory studies, research suggests it may influence dopamine production, a neurotransmitter involved in multiple neural pathways. This mechanism appears distinct from other compounds studied for similar research applications, such as PDE-5 inhibitors, which primarily affect vascular function by widening blood vessels. PT-141’s unique approach makes it an interesting subject for continued laboratory investigation, particularly in models that haven’t responded to other research compounds.
Understanding the Laboratory Findings of PT-141 (Bremelanotide) in Research Models
The theoretical properties observed in animal test subjects suggest that PT-141:
May influence blood pressure parameters
Might affect bladder control mechanisms and pelvic floor muscle function
Could potentially affect vascular responses
May influence performance in behavioral tests
Could play a role in metabolic processes
Might affect stress response markers
Enhanced Physiological Response Research suggests PT-141 might improve certain physiological functions in laboratory models. Studies indicate PT-141 can potentially enhance responses when used in combination with other research compounds like sildenafil in controlled laboratory settings.
Research Findings on PT-141 Laboratory studies suggest PT-141 may influence reproductive system function in both male and female research models by potentially affecting arousal pathways and behavioral responses. Erectile dysfunction results from various studies show that PT-141, particularly when combined with sildenafil, can have significant impacts on sexual health. It appears to work through neural mechanisms rather than vascular pathways, making it an interesting compound for investigating dysfunction models in controlled research environments.
Research Implications of PT-141
PT-141 presents several interesting areas for scientific investigation that make it a compelling subject for laboratory research. Some of the notable research findings include:
Influence on Behavioral Responses: Research suggests PT-141 may significantly affect behavioral patterns in both male and female research models, making it a promising compound for investigating desire mechanism pathways.
Effects on Physiological Function: Laboratory studies indicate that PT-141 might improve certain physiological responses in male research models, providing potential new avenues for scientific inquiry.
Impact on Satisfaction Metrics: Research models demonstrate that PT-141 may enhance satisfaction-related behaviors in both male and female test subjects, contributing to a broader understanding of these mechanisms.
Novel Mechanism of Action: Unlike other compounds investigated for similar purposes, PT-141 appears to work through different pathways, making it a valuable tool for researchers exploring alternative mechanisms.
Laboratory Studies and Research Findings
PT-141 has been examined in numerous scientific investigations, which have explored its properties and effects in controlled laboratory settings. One significant study is the RECONNECT investigation, a 52-week extended observation of two phase 3 research projects. This study documented the extended properties of PT-141 in female research models. Additionally, a study published in the Journal of Sexual Medicine examined the effects of PT-141 in male research models. These investigations highlight PT-141’s potential value in various laboratory research applications.
PT-141 OBSERVED EFFECTS, Increased Sexual Desire, and Behavioral Responses
Some observed effects in research settings include:
Flushing responses
Cranial discomfort
Gastrointestinal observations
Localized reactions at administration sites
Respiratory changes
Energy level alterations
Sensory perception changes
Balance disruptions
Nasal passage effects
Pigmentation alterations
Administration Protocols: In laboratory settings, PT-141 is typically administered via subcutaneous injection. Researchers note that administration timing relative to observation periods may affect research outcomes. The optimal quantities vary depending on research parameters and model responses. It is important to consider the timing of administration relative to sexual activity to ensure accurate and relevant results.
Benefits of PT-141
Enhanced Erectile Response and Increased Sexual Desire in Men
Research suggests that PT-141 can significantly improve erectile function in research models of erectile dysfunction. Laboratory trials have demonstrated that PT-141 increases both the frequency and quality of erections in these models, leading to enhanced overall satisfaction metrics. Additionally, research indicates PT-141 has been found to boost sexual desire in male test subjects, which can further improve sexual function parameters. This dual action on both erectile function and sexual desire makes PT-141 a compelling candidate for further investigation in reproductive health research.
Potential Benefits for Female Sexual Dysfunction
PT-141 is also being explored in research settings as a potential compound for female sexual dysfunction models, a condition characterized by decreased desire, arousal, or satisfaction responses. Research suggests that by influencing blood flow to reproductive tissues and enhancing the body’s natural response to sexual stimulation, PT-141 may help improve sexual function parameters in female research models. This could provide a valuable research avenue for investigating female sexual health mechanisms in laboratory settings.
Improved Libido and Sexual Satisfaction
One of the most notable research findings about PT-141 is its ability to influence libido and satisfaction metrics in both male and female research models. Research suggests that by affecting desire pathways and enhancing erectile function in test subjects, PT-141 can lead to more significant responses in laboratory satisfaction metrics. These improvements in research parameters can provide valuable insights into reproductive health mechanisms, making PT-141 a valuable subject for continued scientific investigation.
Administration Protocols for Erectile Dysfunction
In research settings, PT-141 is typically administered either via subcutaneous injection or intranasal application. The quantities used in research vary depending on the specific model and the particular mechanisms being investigated. Generally, laboratory protocols suggest 1.75 mg administered subcutaneously or intranasally as appropriate for the research design. Maximum quantities in research protocols typically do not exceed 2.5 mg per administration, with a minimum interval of 24 hours between administrations.
It is essential that PT-141 be used exclusively in controlled research environments by qualified investigators. Research facilities considering PT-141 should thoroughly review literature on potential benefits and limitations to determine if it aligns with their investigative objectives.
SOURCING LABORATORY-GRADE PT-141 FOR RESEARCH
When seeking research peptides for laboratory applications, it is crucial to source from a reputable facility to ensure the integrity of your scientific investigations.
Loti Labs provides research-grade compounds at competitive prices, accompanied by comprehensive quality control documentation. We offer detailed technical support and a fair return policy for our laboratory-grade PT-141. Research suggests PT-141 does not significantly affect vascular systems, potentially making it suitable for certain specialized research applications.
Visit our website or contact our research support team today for laboratory-grade PT-141.
Clayton AH, Lucas J, DeRogatis LR, Jordan R. Phase I randomized placebo-controlled, double-blind study of the safety and tolerability of bremelanotide coadministered with ethanol in healthy male and female participants. Clin Ther. 2017;39:514–526.e14. [PubMed]
Bremelanotide (Vyleesi) for hypoactive sexual desire disorder. Med Lett Drugs Ther. 2019;61(1577):114–6. [PubMed]
Dhillon S, Keam SJ. Bremelanotide: First Approval. Drugs. 2019;79:1599–606. [PubMed]
Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, et al. Bremelanotide for treating hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134:899–908. [PMC free article] [PubMed]
Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134:909–17. [PMC free article] [PubMed]
